A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
Clinical trial NCT05013229 · COMPLETED
Trial details
- NCT number
- NCT05013229
- Sponsor
- Novo Nordisk A/S
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-30
- Primary completion
- 2023-11-14
- Enrollment
- 679
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.